A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) (NCT06979336)

🧪 Interventions in This Study

• RO7837195 (DRUG)
• RO7837195 Matched Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (106 Sites)

Showing the first 25 of 106 sites.

• Gastro Care Institute — Lancaster, California
• Medical Associates Research Group, Inc. — San Diego, California
• Peak Gastroenterology Associates — Colorado Springs, Colorado
• Clinical Research of Osceola, LLC — Kissimmee, Florida
• University of Chicago Medical Center — Chicago, Illinois
• Intercity Gastroenterology — Fresh Meadows, New York
• Monroe Biomedical Research — Monroe, North Carolina
• University of Utah Hospitals & Clinics — Salt Lake City, Utah
• Mater Misericordiae Limited — South Brisbane, Queensland
• Royal Melbourne Hospital — Parkville VIC, Victoria
• Fiona Stanley Hospital — Murdoch, Western Australia
• HUWC - UFC - Hospital Universitrio Walter Cantdio - Universidade Federal do Cear — Fortaleza, Ceará
• L2IP ?Instituto de Pesquisas Clínicas Ltda. — Brasília, Federal District
• Chronos Pesquisa Clinica — Brasília, Federal District
• Hospital Felicio Rocho — Belo Horizonte, Minas Gerais
• Associao Paranaense de Cultura APC — Curitiba, Paraná
• Centro Digestivo de Curitiba — Curitiba, Paraná
• Hospital de Clnicas de Porto Alegre — Porto Alegre, Rio Grande do Sul
• Hospital Ernesto Dornelles — Porto Alegre, Rio Grande do Sul
• Newdata Clinical Trials — Aracaju, Sergipe
• CECIP - Centro de Estudos Clínicos do Interior Paulista — Ja, São Paulo
• Pesquisare Saude — Santo André, São Paulo
• Kaiser Clinica — São José do Rio Preto, São Paulo
• Instituto de Assistencia Medica ao Servidor Publico Estudo Estadual — São Paulo, São Paulo
• BR Trials - Ensaios Clnicos e Consultoria — São Paulo, São Paulo

📞 Contact the Study Coordinator

Phone: (888) 662-6728

Email: global-roche-genentech-trials@gene.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ulcerative Colitis

• A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) — Dothan, Alabama
• Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis — San Diego, California
• A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants — Eden Prairie, Minnesota
• CP101 for the Treatment of Ulcerative Colitis — Boston, Massachusetts
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Los Angeles, California
• Angiographic Delivery of AD-MSC for Ulcerative Colitis — Rochester, Minnesota

Explore by condition: All Ulcerative Colitis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.